ASCO Annual Meeting | Conference

Frontline Toripalimab Plus Gemcitabine/Cisplatin Significantly Improves PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

June 3rd 2021

The addition of the immunotherapy agent toripalimab to gemcitabine plus cisplatin demonstrated superior progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to data from the phase 3 JUPITER-02 trial.

177Lu-PSMA-617 Plus Standard of Care Improves OS in mCRPC

June 3rd 2021

177Lu-PSMA-617, a targeted radioligand therapy, plus standard of care induced approximately a 40% reduction in the risk of death vs SOC alone in men with progressive PSMA-positive metastatic castration-resistant prostate cancer.

Cancer Experts Preview Pivotal Trials at ASCO 2021

May 28th 2021

Experts in breast cancer, gynecologic malignancies, lung cancer, multiple myeloma, gastrointestinal cancers, and genitourinary cancers shared their perspectives on the biggest abstracts being presented at the 2021 ASCO Annual Meeting.

States With Lower Medicaid Eligibility Limits May Have Worse Survival Rates Among Patients with Cancer

May 19th 2021

Patients with cancer who live in states with lower Medicaid income eligibility limits had worse long-term survival outcomes compared with those with higher eligibility limits.

Relatlimab Plus Nivolumab More Than Doubles PFS in Frontline Advanced Melanoma

May 19th 2021

The addition of relatlimab to nivolumab more than doubled the median progression-free survival compared with nivolumab alone in patients with previously untreated, unresectable or metastatic melanoma.

Screening, Vaccination Guidance May Be Responsible for Decline in HPV-Related Cervical Cancer

May 19th 2021

Evidence from a population-based study on the incidence of human papillomavirus–related cancers indicate a marked decline in cervical carcinoma, potentially due to clear guidance regarding screening measures and HPV vaccination for vulnerable patient groups.

Adjuvant Atezolizumab Significantly Improves DFS in Early-Stage NSCLC

May 19th 2021

Adjuvant treatment with atezolizumab led to a significant improvement in disease-free survival vs best supportive care in patients with stage II to IIIA non–small cell lung cancer, particularly those with PD-L1–positive tumors, according to findings from the phase 3 IMpower010 trial.

Increased PSA Screening Reduces Prostate Cancer–Specific Mortality in Younger African Americans

May 19th 2021

An increase in the frequency of prostate-specific antigen (PSA) screening was associated with a nearly 25% reduction in prostate cancer–specific mortality in younger African Americans, according to data from a study presented in a presscast held ahead of the 2021 ASCO Annual Meeting.

COSMIC-021 Data Affirm Activity of Cabozantinib/Atezolizumab in mCRPC

June 8th 2020

Neeraj Agarwal, MD, discusses the COSMIC-021 trial, the findings from cohort 6 in metastatic castration-resistant prostate cancer, and the planned phase 3 trial that will evaluate the combination on a larger scale.

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

June 5th 2020

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Dr. Mascarenhas on the Impact of Ruxolitinib on the Myelofibrosis Treatment Paradigm

June 5th 2020

John O. Mascarenhas, MD, discusses the impact of ruxolitinib in the myelofibrosis treatment paradigm.

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer

June 5th 2020

William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.

Dr. Wolf on Updated Findings With Capmatinib in METex14-Mutant NSCLC

June 4th 2020

Jüergen Wolf, MD, discusses data the phase 2 GEOMETRY mono-1 trial with capmatinib (Tabrecta) in patients with METex14-mutated or high MET amplified advanced non–small cell lung cancer.

Pevonedistat/Azacitidine Shows Favorable Activity in Higher-Risk MDS/CMML, Low-Blast AML

June 3rd 2020

The combination of pevonedistat and azacitidine led to a trend toward improved event-free survival and a numerical improvement in overall survival versus azacitidine alone in patients with higher-risk myelodysplastic syndrome/chronic myelomonocytic leukemia, and low-blast acute myelogenous leukemia.

Dr. Zakashansky on the Benefit of Maintenance Olaparib in BRCA+ Ovarian Cancer

June 3rd 2020

Konstantin Zakashansky, MD, discusses final overall survival data from the phase 3 SOLO2 trial evaluating maintenance olaparib (Lynparza) in platinum-sensitive, relapsed ovarian cancer with a BRCA mutation.

CD71-Directed Probody-Drug Conjugate Shows Safety, Signals of Activity in Advanced Solid Tumors

June 2nd 2020

The CD71-directed probody-drug conjugate of monomethyl auristatin E CX-2029 showed tolerability and antitumor activity in patients with advanced cancer.

Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC

June 2nd 2020

The addition of veliparib to cisplatin resulted in a significant improvement in progression-free survival and a trend toward improved overall survival in patients with BRCA-like triple-negative breast cancer.

Dr. Poveda on the Results of the SOLO2 Trial in Ovarian Cancer

June 2nd 2020

Andres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.

Dr. Richardson on Phase 1 Data With CC-92480 in Multiple Myeloma

June 2nd 2020

Paul G. Richardson, MD, discusses phase 1 data (NCT03374085) with CC-92480 in multiple myeloma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

June 2nd 2020

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).